Geras Solutions provides a digital platform for cognitive assessment and decision support in dementia diagnosis, utilizing validated screening tests that can be administered by patients at home or in clinical settings. This technology enhances diagnostic accuracy and efficiency, freeing up healthcare resources while delivering comprehensive data for informed clinical decision-making.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing dementia and other cognitive impairments often requires extensive in-clinic evaluations, placing a burden on healthcare resources and limiting patient access, particularly in remote areas or for those with mobility issues. Traditional paper-based cognitive assessments can be time-consuming, lack sensitivity, and may not capture the full spectrum of cognitive decline.
Solution
Geras Solutions offers a digital platform designed to streamline and enhance the process of cognitive assessment for dementia diagnosis. The platform utilizes validated cognitive screening tests that can be administered by patients and their caregivers at home or in clinical settings via tablet. The tool collects data on memory, visuospatial ability, executive functions, attention/working memory, language, and orientation. Results are automatically interpreted and presented in a dedicated interface for healthcare professionals, providing a comprehensive decision support system. The platform also facilitates anamnesis, gathering patient history and symptom information, and incorporates a neurocognitive symptom survey for caregiver input.
Target Audience
The primary target audience includes healthcare providers such as general practitioners, neurologists, and geriatricians involved in dementia diagnosis and cognitive assessment, as well as hospitals and memory clinics.
Features
- Digital cognitive screening tests based on traditional methods (MoCA, MMSE, clock-test) with enhanced sensitivity and specificity
- Remote administration capabilities, allowing patients to complete assessments at home or in the clinic
- Automated interpretation of test results with cut-off scores for identifying subjective cognitive decline, mild cognitive impairment, and suspected dementia
- Anamnesis module for capturing patient history, cognitive symptoms, health status, and lifestyle factors
- Neurocognitive Symptom Questionnaire (CIMP-QUEST) for gathering caregiver perspectives on symptom development
- Direct compilation of results into a clinical decision support tool for healthcare professionals
- Integration of FINGER-study based risk reduction tools within the "Minnesmottagningen" app, providing patients and relatives with information and support related to diet, exercise, social interaction and brain training activities
- CE-marked medical device (Class I according to MDD, Class IIa according to MDR)